Executive Spotlights

Teva Announces Appointment of Richard Francis as President and CEO

Tel Aviv, Israel, November 21, 2022 (Business Wire) -- Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) (NYSE and TASE: TEVA), today announced that the Company’s Board of Directors has appointed Richard Francis as President and Chief Executive Officer, effective January 1, 2023. In order to facilitate an orderly transition, Kåre Schultz and the Teva Board of Directors have mutually agreed that Mr. Schultz will retire from his current position as Chief Executive Officer, effective December 31, 2022.


Read full article here.

Recent Posts

See All
Life Science Headlines